Why Revolution Medicines May Be Big Pharma's Next Takeover Target

Impact · against what's priced in

Revolution Medicines' valuation is driven by strong Phase 3 survival data and regulatory progress for daraxonrasib, making it a primary M&A target for Merck and BMY. While the clinical success is clear, the high market cap ($44.1B) and recent insider selling suggest much of the current optimism is already reflected in the price.

RVMD+0.60

No priced-in read yet